Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

The agency weighed safety data and a new dosing regimen to recommend approval of the treatment for early Alzheimer's disease in certain patients.

Elevidys, which is also facing regulatory hurdles in the US, was developed by Sarepta Therapeutics but is sold by Roche outside of the US.

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

Researchers explored changes in survival outcomes and financial strain for NSCLC patients during a time when new targeted ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

The reorganization and pipeline prioritization is expected to extend the company's operational runway into 2027 and support its long-term growth.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about federal cuts.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.